Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sell to Hold. Analyst Price Forecast Suggests 10.64% Upside As of ...

Arizona State Retirement System boosted its position in shares of Vertex, Inc. (NASDAQ:VERX – Free Report) by 7.3% during the fourth quarter, according to the company in its most recent Form 13F ...

The project has been developed and is owned by Green Tie Capital, and EPC is contracted by Elmya, featuring advanced solar technology including 33,600 Vertex modules and 580 Vanguard 1P trackers.